From Myeloma to Plasma Cell Leukemia, Persistent Inequalities

作     者：Mamadou Wague Gueye Nata Dieng Maguette Ndoye Mor Ngom Sokhna Moumi Mbacké Daffé Papa Silman Diawara Macoura Gadji Ndèye Marième Diagne Bécaye Fall Mamadou Wague Gueye;Nata Dieng;Maguette Ndoye;Mor Ngom;Sokhna Moumi Mbacké Daffé;Papa Silman Diawara;Macoura Gadji;Ndèye Marième Diagne;Bécaye Fall

作者机构：Laboratory Federation Hôpital Principal de Dakar (HPD) Dakar Senegal Onco-Hematology Hôpital Principal de Dakar (HPD) Dakar Sénégal Biological and Oncological Hematology Department (BOHD) Centre National de Transfusion Sanguine (CNTS)/FMPOS-UCAD Dakar Sénégal 

出 版 物：《Open Journal of Blood Diseases》 (血液病期刊（英文）)

年 卷 期：2023年第13卷第4期

页      面：133-140页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Multiple Myeloma Plasma Cells Leukemia Personalized Medicine Risk Stratification 

摘      要：Multiple myeloma (MM) is both a complex and heterogeneous disease. Cytogenetic and molecular abnormalities lead to resistance to treatment and transformation to plasma cell leukemia, which is defined by the presence in circulating blood of plasma cells over 2 G/L, or more than 20% of leukocytes. It is an uncommon hematological malignancy with a poor prognosis. Against this backdrop, we report an observation of multiple myeloma transformed into plasma cell leukemia diagnosed at the Hôpital Principal de Dakar (HPD) that occurred on a 64-year-old man with a history of thyroidectomy followed for multiple myeloma presenting with Salmon et Durie stage IIIA and ISS stage I. Despite a marked improvement in management strategy, myeloma remains an almost invariably incurable disease. However, the development of genetic and molecular biomarkers is necessary to improve its prognosis.